瑞典乳腺癌组91放疗随机临床试验中不同乳腺癌亚型保乳术后对放疗的反应
该随机临床试验从1991至1997年纳入1003例淋巴结阴性I-II期乳腺癌保乳术后患者,比较放疗与否,对958例肿瘤进行亚型分型。放疗降低管腔A型、管腔B型和三阴性肿瘤的10年同侧乳腺肿瘤复发累积发生率,但对HER2阳性肿瘤未见降低;亚型间放疗效应总体差异证据弱(P=0.21)。
要点
- 放疗降低管腔A样肿瘤10年同侧乳腺肿瘤复发(19% vs 9%;P=0.001)。
- 放疗降低三阴性肿瘤乳腺癌死亡风险(HR 0.35;P=0.06),但未达统计学显著。
- 假定临床低风险组未放疗仍有较高复发风险,放疗降低10年复发(20% vs 6%;P=0.008)。
核心结论
- 亚型不能预测放疗反应,但本研究中HER2阳性肿瘤似乎最抗拒放疗,而三阴性肿瘤对乳腺癌死亡影响最大。
- 放疗在推测为低风险的管腔A样肿瘤中效果极佳。
研究设计与样本
- 瑞典乳腺癌组91放疗随机临床试验,1991至1997年将1003例淋巴结阴性I-II期乳腺癌保乳术后患者随机分配至放疗或不放疗。
- 全身辅助治疗使用较少(8%);对958例肿瘤采用组织微阵列免疫组化和原位杂交进行亚型分型。
主要发现
- 放疗降低10年内同侧乳腺肿瘤复发作为首次事件的累积发生率:管腔A样肿瘤19% vs 9%(P=0.001),管腔B样肿瘤24% vs 8%(P<0.001),三阴性肿瘤21% vs 6%(P=0.08)。
- 放疗未降低HER2阳性(管腔和非管腔)肿瘤的同侧乳腺肿瘤复发:15% vs 19%(P=0.6);亚型间放疗效应总体差异证据弱(P=0.21)。
- 放疗降低三阴性肿瘤的乳腺癌死亡率(HR 0.35;P=0.06),但未降低其他亚型的乳腺癌死亡率。
- 放疗未改善任何亚型的全因死亡。
- 假定临床低风险组未放疗仍有较高同侧乳腺肿瘤复发风险,放疗降低10年后同侧乳腺肿瘤复发作为首次事件(20% vs 6%;P=0.008),但对乳腺癌死亡或全因死亡无影响。
关键数值与推荐
- 管腔A样肿瘤10年同侧乳腺肿瘤复发累积发生率:放疗组9% vs 未放疗组19%(P=0.001)。
- 管腔B样肿瘤10年同侧乳腺肿瘤复发累积发生率:放疗组8% vs 未放疗组24%(P<0.001)。
- 三阴性肿瘤10年同侧乳腺肿瘤复发累积发生率:放疗组6% vs 未放疗组21%(P=0.08)。
- HER2阳性(管腔和非管腔)肿瘤同侧乳腺肿瘤复发:放疗组19% vs 未放疗组15%(P=0.6)。
- 三阴性肿瘤乳腺癌死亡:HR 0.35(P=0.06)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To evaluate the effect of adjuvant radiotherapy (RT) after breast conservation surgery in different breast cancer subtypes in a large, randomized clinical trial with long-term follow-up. Patients and Methods Tumor tissue was collected from 1,003 patients with node-negative, stage I and II breast cancer who were randomly assigned in the Swedish Breast Cancer Group 91 Radiotherapy trial between 1991 and 1997 to breast conservation surgery with or without RT. Systemic adjuvant treatment was sparsely used (8%). Subtyping was performed with immunohistochemistry and in situ hybridization on tissue microarrays for 958 tumors. Results RT reduced the cumulative incidence of ipsilateral breast tumor recurrence (IBTR) as a first event within 10 years for luminal A-like tumors (19% v 9%; P = .001), luminal B-like tumors (24% v 8%; P < .001), and triple-negative tumors (21% v 6%; P = .08), but not for human epidermal growth factor receptor 2-positive (luminal and nonluminal) tumors (15% v 19%; P = .6); however, evidence of an overall difference in RT effect between subtypes was weak ( P = .21). RT reduced the rate of death from breast cancer (BCD) for triple-negative tumors (hazard ratio, 0.35; P = .06), but not for other subtypes. Death from any cause was not improved by RT in any subtype. A hypothesized clinical low-risk group did not have a low risk of IBTR without RT, and RT reduced the rate of IBTR as a first event after 10 years (20% v 6%; P = .008), but had no effect on BCD or death from any cause. Conclusion Subtype was not predictive of response to RT, although, in our study, human epidermal growth factor receptor 2-positive tumors seemed to be most radioresistant, whereas triple-negative tumors had the largest effect on BCD. The effect of RT in the presumed low-risk luminal A-like tumors was excellent.
引用
- Sjöström M, Lundstedt D, Hartman L, et al. Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. J Clin Oncol. 2017. PMID: 28759347. doi:10.1200/JCO.2017.72.7263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。